It is expected that large numbers of healthcare workers will experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. The purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers caring for COVID-19 patients. There are two phases of the study. All participants will take part in Phase I, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. Participants will be randomly assigned to the narrative writing intervention or medical music intervention. After Phase I, participants will be re-assessed. Healthcare workers who meet criteria for PTSD will be given the option to participate in Phase II of the study, in which they will be offered a choice between one of two evidence-based treatments for PTSD: Interpersonal Therapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minute sessions scheduled twice weekly. Participants will be allowed to choose a preferred treatment in Phase II. After Phase II participants will complete a final assessment concluding the study. All interventions will be offered using distance technology.
Behavioral: Medical Music
Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
Behavioral: Narrative Writing
Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
Behavioral: Prolonged Exposure Therapy
Psychotherapy including imaginal exposure for PTSD
Behavioral: Interpersonal Psychotherapy
Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
Inclusion Criteria:
- Any healthcare worker providing medical care or support for COVID-19 patients
- English-speaking
- Age >18
- Medically stable
- Able to provide informed consent and function at an intellectual level sufficient to
allow accurate completion of all assessment instruments
- If on psychotropic medication stable for prior 60 days
For phase II additional inclusion criteria:
- Current diagnosis of PTSD
Exclusion Criteria:
- Current significant unstable medical illness precluding regular session attendance or
assessment completion
- Participants who in the investigator's judgment pose a current homicidal, suicidal, or
other risk
- Lifetime or current diagnosis of schizophrenia or other psychotic disorder
- Participation in a clinical trial or concurrent evidence-based treatment for
psychiatric conditions or PTSD during the previous 3 months.
Weill Cornell Medicine
New York, New York, United States
Investigator: Olivia Baryluk, BS
Investigator: JoAnn Difede, PhD
Olivia Baryluk, BS
212-821-0783
olb4002@med.cornell.edu
JoAnn Difede, PhD, Principal Investigator
Weill Medical College of Cornell University